Traduction de «patient asymptomatique à long terme » (Français → Anglais) :

They range from chronic diseases (cardiovascular, cancer, diabetes) together with overweight and obesity, infectious (HIV/AIDS, tuberculosis) and neurodegenerative diseases (exacerbated by an increasingly ageing population), to social isolation, reduced wellbeing, increased dependency of patients on formal and informal care, and multiple exposure to environmental factors with unknown long-term health consequences.

Action n° 6: To promote, in a staged approach, unprecedented collaborative research and development efforts to bring new antibiotics to patients by: Launching rapidly with EFPIA[12], within the IMI-Joint Undertaking, a programme for research on new antibiotics aimed at improving the efficiency of research and development of new antibiotics through unprecedented open sharing of knowledge. Establishing an overarching framework agreement with the industry, defining objectives, commitments, priorities, principles and modes of action for public-private collaboration in a longer term ...[+++] perspective. Mobilising adequate resources, within IMI in particular (and its possible successor), FP7 and in the longer term the forthcoming research and innovation programme 2014-2020 (Horizon 2020), in order to support research and development work, based on criteria and modalities adapted to the specific needs and challenges of antibiotic development. Use the flexibility in the current pharmaceutical legislation to give rapid authorisation to new antibiotics and work with stakeholders and the Member States' authorities towards the establishment of adequate market and pricing conditions for new antibiotics. Ensure conditions for and implement fast track procedures for the marketing authorisation of new antimicrobials.

Action n° 6: To promote, in a staged approach, unprecedented collaborative research and development efforts to bring new antibiotics to patients by: Launching rapidly with EFPIA[12], within the IMI-Joint Undertaking, a programme for research on new antibiotics aimed at improving the efficiency of research and development of new antibiotics through unprecedented open sharing of knowledge. Establishing an overarching framework agreement with the industry, defining objectives, commitments, priorities, principles and modes of action for public-private collaboration in a longer term ...[+++] perspective. Mobilising adequate resources, within IMI in particular (and its possible successor), FP7 and in the longer term the forthcoming research and innovation programme 2014-2020 (Horizon 2020), in order to support research and development work, based on criteria and modalities adapted to the specific needs and challenges of antibiotic development. Use the flexibility in the current pharmaceutical legislation to give rapid authorisation to new antibiotics and work with stakeholders and the Member States' authorities towards the establishment of adequate market and pricing conditions for new antibiotics. Ensure conditions for and implement fast track procedures for the marketing authorisation of new antimicrobials.

Calls on the Commission and the Member States to ensure that equitable access to healthcare and treatment options for older patients are included in their health policies and programmes and to make adequate access to healthcare and treatments for older people a priority for ‘2012 European Year for Active Ageing and Intergenerational Solidarity’; calls on the Member States to promote initiatives in order to tackle social isolation in elderly patients as it has a significant impact on patients’ longer-term health; stresses the need for the European Union and its Member States to anticipate, through an appropriate long-term strategy, the ...[+++]social and economic impact of the ageing of the European population, in order to guarantee the financial and organisational sustainability of healthcare systems, as well as equal and continued delivery of care for patients;

Innovative approaches in areas such as public transport, the organization of public space and the protection of borders can be envisaged. Space, offers great scope for high technology innovation over time (in particular public investors in the application of Galileo [17] and GMES (Global Monitoring for Environment and Security), the Commission's flagship space programmes. These need to share their knowledge of the system and its scope for business with potential downstream users in the space and non-space sectors, to raise their awareness of potential space-based solutions). Transport, where the demand for energy efficiency provides grea ...[+++]t opportunities. Marine technologies and products allowing for new uses of the sea such as deep sea drilling, blue biotech exploitation, offshore mariculture and renewable energies, ocean space monitoring and surveillance technologies offer promising scope. Health, which has a huge growth potential for innovative products and services (including in particular e-Health, and the provision of customized solutions to allow elderly people to continue to live independently, pharmaceuticals and medical devices where innovation can bring direct benefits to patients and improve competitiveness), or well-being and culture (for instance creative content services, which gain a new dimension with the rollout of broadband networks, allowing citizens and businesses to access all kind of creative contents such as audiovisual, games, cultural information at home and in mobility) are examples of markets where the public sector has a role to play.

This group covers the services of general and specialist hospitals, the services of medical centres, maternity centres, nursing homes and convalescence homes which chiefly provide in-patient health care, the services of institutions serving old people in which medical monitoring is an essential component and the services of rehabilitation centres providing in-patient health care and rehabilitative therapy where the objective is to treat the patient rather than to provide long-term support.